{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T00:11:54Z","timestamp":1793059914433,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1038\/s41440-025-02375-w","type":"journal-article","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T09:13:30Z","timestamp":1758273210000},"page":"2864-2875","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Diagnostic performance of 24-hour urinary aldosterone for primary aldosteronism in patients with or without discontinuation of antihypertensive medications"],"prefix":"10.1038","volume":"48","author":[{"given":"Mei","family":"You","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huandong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongping","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushuang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruomei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hexuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbo","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiming","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhencheng","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,19]]},"reference":[{"key":"2375_CR1","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/s41574-022-00730-2","volume":"18","author":"AF Turcu","year":"2022","unstructured":"Turcu AF, Yang J, Vaidya A. Primary aldosteronism - a multidimensional syndrome. Nat Rev Endocrinol. 2022;18:665\u201382.","journal-title":"Nat Rev Endocrinol"},{"key":"2375_CR2","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/j.jacc.2017.01.052","volume":"69","author":"S Monticone","year":"2017","unstructured":"Monticone S, Burrello J, Tizzani D, Bertello C, Viola A, Buffolo F, et al. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. J Am Coll Cardiol. 2017;69:1811\u201320.","journal-title":"J Am Coll Cardiol"},{"key":"2375_CR3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S2213-8587(17)30319-4","volume":"6","author":"S Monticone","year":"2018","unstructured":"Monticone S, D\u2019Ascenzo F, Moretti C, Williams TA, Veglio F, Gaita F, et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diab Endocrinol. 2018;6:41\u201350.","journal-title":"Lancet Diab Endocrinol"},{"key":"2375_CR4","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1001\/jamasurg.2021.0254","volume":"156","author":"YY Liu","year":"2021","unstructured":"Liu YY, King J, Kline GA, Padwal RS, Pasieka JL, Chen G, et al. Outcomes of a specialized clinic on rates of investigation and treatment of primary Aldosteronism. JAMA Surg. 2021;156:541\u20139.","journal-title":"JAMA Surg"},{"key":"2375_CR5","doi-asserted-by":"publisher","first-page":"289","DOI":"10.7326\/M20-4873","volume":"174","author":"JB Cohen","year":"2021","unstructured":"Cohen JB, Cohen DL, Herman DS, Leppert JT, Byrd JB, Bhalla V. Testing for Primary Aldosteronism and Mineralocorticoid receptor antagonist use among U.S. Veterans : A retrospective cohort study. Ann Intern Med. 2021;174:289\u201397.","journal-title":"Ann Intern Med"},{"key":"2375_CR6","doi-asserted-by":"publisher","unstructured":"Leung AA, Kline G A new pathway for primary aldosteronism treatment. Lancet. 2025; https:\/\/doi.org\/10.1016\/s0140-6736(25)00051-0","DOI":"10.1016\/s0140-6736(25)00051-0"},{"key":"2375_CR7","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.tcm.2021.03.005","volume":"32","author":"J Funder","year":"2022","unstructured":"Funder J. Primary aldosteronism. Trends Cardiovasc Med. 2022;32:228\u201333.","journal-title":"Trends Cardiovasc Med"},{"key":"2375_CR8","doi-asserted-by":"publisher","unstructured":"Azizan EAB, Drake WM, Brown MJ. Primary aldosteronism: molecular medicine meets public health. Nat Rev Nephrol. 2023; https:\/\/doi.org\/10.1038\/s41581-023-00753-6","DOI":"10.1038\/s41581-023-00753-6"},{"key":"2375_CR9","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/S2213-8587(21)00210-2","volume":"9","author":"M Reincke","year":"2021","unstructured":"Reincke M, Bancos I, Mulatero P, Scholl UI, Stowasser M, Williams TA. Diagnosis and treatment of primary aldosteronism. Lancet Diab Endocrinol. 2021;9:876\u201392.","journal-title":"Lancet Diab Endocrinol"},{"key":"2375_CR10","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1210\/jc.2015-4061","volume":"101","author":"JW Funder","year":"2016","unstructured":"Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101:1889\u2013916.","journal-title":"J Clin Endocrinol Metab"},{"key":"2375_CR11","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1161\/HYPERTENSIONAHA.107.093468","volume":"50","author":"P Mulatero","year":"2007","unstructured":"Mulatero P, Bertello C, Garrone C, Rossato D, Mengozzi G, Verhovez A, et al. Captopril test can give misleading results in patients with suspect primary aldosteronism. Hypertension. 2007;50:e26\u20137.","journal-title":"Hypertension"},{"key":"2375_CR12","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1111\/j.1365-2265.1992.tb02252.x","volume":"36","author":"C Hambling","year":"1992","unstructured":"Hambling C, Jung RT, Gunn A, Browning MC, Bartlett WA. Re-evaluation of the captopril test for the diagnosis of primary hyperaldosteronism. Clin Endocrinol (Oxf). 1992;36:499\u2013503.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2375_CR13","doi-asserted-by":"publisher","first-page":"10","DOI":"10.7326\/M20-0065","volume":"173","author":"JM Brown","year":"2020","unstructured":"Brown JM, Siddiqui M, Calhoun DA, Carey RM, Hopkins PN, Williams GH, et al. The unrecognized prevalence of primary Aldosteronism: A cross-sectional study. Ann Intern Med. 2020;173:10\u201320.","journal-title":"Ann Intern Med"},{"key":"2375_CR14","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/S0272-6386(01)80117-7","volume":"37","author":"BJ Gallay","year":"2001","unstructured":"Gallay BJ, Ahmad S, Xu L, Toivola B, Davidson RC. Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am J Kidney Dis. 2001;37:699\u2013705.","journal-title":"Am J Kidney Dis"},{"key":"2375_CR15","unstructured":"Joint Committee for Guideline Revision. 2018 Chinese Guidelines for Prevention and Treatment of Hypertension-A report of the Revision Committee of Chinese Guidelines for Prevention and Treatment of Hypertension. J Geriatr Cardiol. 2019;16:182\u2013241."},{"key":"2375_CR16","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1111\/jch.13960","volume":"22","author":"H Zhang","year":"2020","unstructured":"Zhang H, Li Q, Liu X, Zhao Z, He H, Sun F, et al. Adrenal artery ablation for primary aldosteronism without apparent aldosteronoma: An efficacy and safety, proof-of-principle trial. J Clin Hypertens. 2020;22:1618\u201326.","journal-title":"J Clin Hypertens"},{"key":"2375_CR17","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1507\/endocrj.EJ21-0508","volume":"69","author":"M Naruse","year":"2022","unstructured":"Naruse M, Katabami T, Shibata H, Sone M, Takahashi K, Tanabe A, et al. Japan Endocrine Society clinical practice guideline for the diagnosis and management of primary aldosteronism 2021. Endocr J. 2022;69:327\u201359.","journal-title":"Endocr J"},{"key":"2375_CR18","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1161\/HYPERTENSIONAHA.113.02097","volume":"63","author":"GP Rossi","year":"2014","unstructured":"Rossi GP, Auchus RJ, Brown M, Lenders JW, Naruse M, Plouin PF, et al. An expert consensus statement on use of adrenal vein sampling for the subtyping of primary aldosteronism. Hypertension. 2014;63:151\u201360.","journal-title":"Hypertension"},{"key":"2375_CR19","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1161\/HYPERTENSIONAHA.119.13358","volume":"74","author":"Y Cui","year":"2019","unstructured":"Cui Y, Wu H, Li Q, Liao J, Gao P, Sun F, et al. Impairment of bitter taste sensor transient receptor potential channel m5-mediated aversion aggravates high-salt intake and hypertension. Hypertension. 2019;74:1021\u201332.","journal-title":"Hypertension"},{"key":"2375_CR20","doi-asserted-by":"publisher","unstructured":"Bu X, Sun F, Li Q, Zhang H, Jiang N, Luo Y, et al. High salt intake exacerbates aldosterone-related target organ damage in patients with primary aldosteronism. Hypertens Res. 2025; https:\/\/doi.org\/10.1038\/s41440-025-02270-4","DOI":"10.1038\/s41440-025-02270-4"},{"key":"2375_CR21","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1210\/endrev\/bnad026","volume":"45","author":"N Mullen","year":"2024","unstructured":"Mullen N, Curneen J, Donlon PT, Prakash P, Bancos I, Gurnell M, et al. Treating primary aldosteronism-induced hypertension: novel approaches and future outlooks. Endocr Rev. 2024;45:125\u201370.","journal-title":"Endocr Rev"},{"key":"2375_CR22","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1038\/s41440-019-0284-9","volume":"42","author":"S Umemura","year":"2019","unstructured":"Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019). Hypertens Res. 2019;42:1235\u2013481.","journal-title":"Hypertens Res"},{"key":"2375_CR23","first-page":"58","volume":"4","author":"Health TWCotARoC, China Di","year":"2024","unstructured":"Health TWCotARoC, China Di. Interpretation of the Annual Report on Cardiovascular Health and Diseases in China 2022. Cardiol Discov. 2024;4:58\u201380.","journal-title":"Cardiol Discov"},{"key":"2375_CR24","doi-asserted-by":"publisher","unstructured":"Wu H, He H, Han T, Tian X, Zhu Z. Targeting cholesterol-dependent adrenal steroidogenesis for management of primary aldosteronism. Trends Endocrinol Metab. 2025; https:\/\/doi.org\/10.1016\/j.tem.2024.12.001","DOI":"10.1016\/j.tem.2024.12.001"},{"key":"2375_CR25","doi-asserted-by":"publisher","unstructured":"Yuan L, Li X, Sun F, Tang Y, Wang W, Liu W, et al. Comparative outcomes of adrenalectomy, mineralocorticoid receptor antagonist, and percutaneous adrenal ablation for primary aldosteronism: a systematic review and network meta-analysis. Am J Hypertens. 2025; https:\/\/doi.org\/10.1093\/ajh\/hpaf029","DOI":"10.1093\/ajh\/hpaf029"},{"key":"2375_CR26","doi-asserted-by":"publisher","first-page":"e3655","DOI":"10.1210\/clinem\/dgab290","volume":"106","author":"A Pecori","year":"2021","unstructured":"Pecori A, Buffolo F, Burrello J, Mengozzi G, Rumbolo F, Avataneo V, et al. Mineralocorticoid receptor antagonist effect on Aldosterone to Renin ratio in patients with primary Aldosteronism. J Clin Endocrinol Metab. 2021;106:e3655\u2013e64.","journal-title":"J Clin Endocrinol Metab"},{"key":"2375_CR27","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1161\/HYPERTENSIONAHA.120.14871","volume":"76","author":"Z Guo","year":"2020","unstructured":"Guo Z, Poglitsch M, Cowley D, Domenig O, McWhinney BC, Ungerer JPJ, et al. Effects of Ramipril on the Aldosterone\/Renin Ratio and the Aldosterone\/Angiotensin II ratio in patients with primary Aldosteronism. Hypertension. 2020;76:488\u201396.","journal-title":"Hypertension"},{"key":"2375_CR28","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1507\/endocrj.EJ13-0060","volume":"60","author":"K Murase","year":"2013","unstructured":"Murase K, Nagaishi R, Takenoshita H, Nomiyama T, Akehi Y, Yanase T. Prevalence and clinical characteristics of primary aldosteronism in Japanese patients with type 2 diabetes mellitus and hypertension. Endocr J. 2013;60:967\u201376.","journal-title":"Endocr J"},{"key":"2375_CR29","doi-asserted-by":"publisher","unstructured":"Ruiz-S\u00e1nchez JG, Fern\u00e1ndez S\u00e1nchez \u00c1, Meneses D. Feasibility of primary aldosteronism diagnosis in initial evaluation without medication withdrawal or confirmatory tests. Endocrine. 2024; https:\/\/doi.org\/10.1007\/s12020-024-03798-0","DOI":"10.1007\/s12020-024-03798-0"},{"key":"2375_CR30","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1097\/HJH.0000000000002047","volume":"37","author":"M Nagasawa","year":"2019","unstructured":"Nagasawa M, Yamamoto K, Rakugi H, Takeda M, Akasaka H, Umakoshi H, et al. Influence of antihypertensive drugs in the subtype diagnosis of primary aldosteronism by adrenal venous sampling. J Hypertens. 2019;37:1493\u20139.","journal-title":"J Hypertens"},{"key":"2375_CR31","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/s12020-023-03520-6","volume":"83","author":"X Li","year":"2024","unstructured":"Li X, Liang J, Hu J, Ma L, Yang J, Zhang A, et al. Screening for primary aldosteronism on and off interfering medications. Endocrine. 2024;83:178\u201387.","journal-title":"Endocrine"},{"key":"2375_CR32","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1530\/EJE-11-0914","volume":"166","author":"M Solar","year":"2012","unstructured":"Solar M, Malirova E, Ballon M, Pelouch R, Ceral J. Confirmatory testing in primary aldosteronism: extensive medication switching is not needed in all patients. Eur J Endocrinol. 2012;166:679\u201386.","journal-title":"Eur J Endocrinol"},{"key":"2375_CR33","first-page":"4125","volume":"104","author":"QT Zhang","year":"2024","unstructured":"Zhang QT, Jin P, Wan JJ, Zhao LL. [Value of 24-hour urinary aldosterone in diagnosis and classification of primary hyperaldosteronism]. Zhonghua Yi Xue Za Zhi. 2024;104:4125\u201331.","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"2375_CR34","doi-asserted-by":"publisher","unstructured":"Kario K, Hoshide S, Mogi M. Hypertension Research global initiatives 2025 added new themes-\u201cimplementation hypertension\u201d and \u201cmorning hypertension\u201d. Hypertens Res. 2025; https:\/\/doi.org\/10.1038\/s41440-024-02095-7","DOI":"10.1038\/s41440-024-02095-7"},{"key":"2375_CR35","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1111\/jch.13058","volume":"19","author":"YC Chia","year":"2017","unstructured":"Chia YC, Buranakitjaroen P, Chen CH, Divinagracia R, Hoshide S, Park S, et al. Current status of home blood pressure monitoring in Asia: Statement from the HOPE Asia Network. J Clin Hypertens. 2017;19:1192\u2013201.","journal-title":"J Clin Hypertens"},{"key":"2375_CR36","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1056\/NEJMoa1304127","volume":"371","author":"D Mozaffarian","year":"2014","unstructured":"Mozaffarian D, Fahimi S, Singh GM, Micha R, Khatibzadeh S, Engell RE, et al. Global sodium consumption and death from cardiovascular causes. N Engl J Med. 2014;371:624\u201334.","journal-title":"N Engl J Med"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02375-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02375-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02375-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T23:02:08Z","timestamp":1762297328000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02375-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,19]]},"references-count":36,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["2375"],"URL":"https:\/\/doi.org\/10.1038\/s41440-025-02375-w","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,19]]},"assertion":[{"value":"5 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}